导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.90% | 1459/4699 |
| 近一周 | -2.63% | 2670/5365 |
| 近一月 | -5.27% | 3074/5324 |
| 近一季 | -9.57% | 3199/5114 |
| 近半年 | -6.79% | 3079/4837 |
| 近一年 | 8.21% | 1196/4300 |
| 近两年 | 72.56% | 921/2924 |
| 近三年 | 36.78% | 799/2228 |
| 成立以来 | 109.08% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.14% 1041/4961 |
19.57% 1287/5312 |
- - |
- - |
| 2025 | 31.60% 1227/4813 |
2.02% 1492/3635 |
1.98% 1970/4076 |
24.82% 1433/4524 |
1.34% 1411/4813 |
| 2024 | 6.25% 1776/3463 |
-2.76% 1428/2808 |
-5.36% 1702/3014 |
16.22% 1505/3129 |
-0.65% 1490/3463 |
| 2023 | -6.34% 831/2656 |
7.71% 529/2280 |
-4.19% 1086/2385 |
-4.78% 1221/2515 |
-4.69% 1144/2655 |
| 2022 | -19.17% 811/2207 |
-14.01% 892/1919 |
2.82% 1255/2016 |
-10.87% 455/2113 |
2.57% 896/2208 |
| 2021 | 15.22% 310/1822 |
-1.95% 557/1255 |
9.24% 577/1330 |
4.20% 374/1466 |
3.23% 457/1822 |
| 2020 | 24.15% 638/1250 |
-3.51% 302/1028 |
17.82% 358/1067 |
6.27% 860/1164 |
2.76% 968/1184 |
| 2019 | 25.09% 608/1092 |
27.51% 344/754 |
-10.02% 710/804 |
2.10% 323/850 |
6.78% 551/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 方正富邦中证500ETF VS. 长安沪深300非周期A(740101) |